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Role of nitric oxide synthase on brain GABA transaminase 
activity and GABA levels
In an attempt to clarify the controversial role of nitric 
oxide (NO) in seizures, the effects of NO on brain 
GABA transaminase (GABA-T) activity and GABA 
levels were investigated. To this aim, the effects of the 
substrate (l-arginine) and inhibitors (Nω-nitro-l-
arginine methyl ester, 7-nitroindazole) of NO synthase 
(NOS) on GABA-T activity and GABA levels in vitro and 
ex vivo were analyzed. In vitro NO diminished GABA-T 
activity and increased GABA. Ex vivo NO modified 
GABA-T activity and GABA levels biphasically. Inhibi-
tion of endothelial and neuronal NOS (eNOS and 
nNOS) had opposite effects on GABA-T activity and 
GABA levels, even during seizures induced by pentylene-
tetrazole. Different effects of NO on GABA-T activity 
and on GABA levels, depending on the NOS isoform 
involved, may explain its contradictory role in seizures, 
the endothelial NOS acting as an anticonvulsant and 
the neuronal NOS as a proconvulsant. nNOS inhibitors 
may represent a new generation of antiepileptics.
Keywords: nitric oxide, GABA-transaminase, GABA, 
seizures
Nitric oxide (NO) is a freely diffusible gas synthesized from the oxidation of l-argi-
nine by one of the isoforms of the enzyme NO synthase (NOS): neuronal (nNOS), endothe-
lial (eNOS) and inducible (iNOS). In the brain, NO acts both as a second messenger and as 
a neurotransmitter/neuromodulator, and influences several physiological functions (1, 2) 
such as: interneuronal communication, synaptic plasticity, memory, intracellular signal 
transmission and mediator release (3). Also, it has been proposed that NO can induce pa-
thologies that can lead to different neurological disorders such as ischemia, stroke and 
epileptiform seizures (2).
The role of NO in epileptogenesis has been examined in a number of ex vivo and in 
vitro studies; however, the results are still contradictory. In the present state of knowledge, 
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the only reasonable conclusion is that NO behaves as a neuromodulador with dual – pro-
convulsive or anticonvulsive – action (4).
The main intracellular effect of NO in the central nervous system (CNS) is the activa-
tion of soluble guanylate cyclase, leading to the synthesis of cyclic guanosine monophos-
phate (cGMP) (5). As an example of the importance of the NO-cGMP pathway, its involve-
ment in the neuroprotective effect of hesperidin in mice could be mentioned (6). However, 
NO also evokes the release of neurotransmitters including acetylcholine, catecholamines 
and neuroactive amino acids such as gamma aminobutyric acid (GABA) (7).
Seizures may appear when the balance between excitatory and inhibitory impulses 
in the brain is perturbed. GABA is considered to be the main inhibitory neurotransmitter 
of the CNS that counterbalances neuronal excitation. One of the strategies to prevent and/
or control convulsions is to increase GABA brain levels through inhibition of GABA trans-
aminase (GABA-T, EC 2.6.1.19), the enzyme responsible for its degradation.  Based on this 
principle, anticonvulsant drugs such as amino oxyacetic acid (AAOA) and antiepileptic 
drugs such as valproic acid (8), vigabatrin (9) and ethanolamine-O-sulfate (10) were de-
signed.
Stimulation of glutamate receptors, mainly of the N-methyl-d-aspartate (NMDA) 
type, is a consequence of the increase in cGMP caused by NO. It has been reported that 
NMDA receptors may contribute to both anti- and pro-convulsant effects of d-penicilla-
mine (11). NMDA receptor activation induces release of GABA from the cerebral cortical 
and striatal neurons (12–14). In addition, it has been reported that the increase in NO 
concentration is associated with the release of GABA in cerebral cortex (7), hippocampus 
(15) and striatum (16–18); however, the mechanisms still remain unclear. As an example, 
it is not clear why moderate and high increases of NO levels had opposite effects on GABA-T 
activity (18). 
Considering the foregoing and the widespread role of NO in the nervous system, we 
conducted an in vitro and ex vivo study in order to explore the possible factors influencing 
the effect of NO on GABA-T activity. To this aim, the effects of promotion of NO synthesis 
induced by l-arginine (l-Arg) on GABA-T activity and GABA levels in whole mouse brain 
were investigated. The effect of NO synthesis inhibition on the described parameters was 
also studied using Nw-nitro-l-arginine-methyl ester (L-NAME), an unspecific inhibitor of 
NOS. Since nNOS is distributed in several sensory pathways (19, 20), 7-nitroindazole (7-
NI), a specific inhibitor of nNOS that administrated in doses up to 80 mg kg-1 was re-
ported to have no effect on the mean arterial pressure (21), was also included in the study. 
Effect of the mentioned drugs on described parameters was also studied during seizures 
induced by pentylenetetrazole (PTZ).
EXPERIMENTAL
Chemicals
l-Arg, L-NAME, 7-NI, AAOA, GABase [a mixture of GABA-T and succinic semialde-
hyde dehydrogenase (SSDH, EC 1.2.1.16) from Pseudomonas fluorescens] and PTZ were pur-
chased from Sigma Chemical Co. (USA). Standard analytical grade laboratory reagents 
were obtained from Merck (Germany) or Sigma-Aldrich Chemical Co. (USA).
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Experiments were conducted in compliance with the Helsinki Guide for the Care and 
Use of Laboratory Animals, adopted and promulgated by the EU Directive 2010/63/EU for 
animal experiments and approved by the institutional committee of ethics of E.N.C.B. 
(Escuela Nacional de Ciencias Biológicas, Ciudad de México, México).
CD1 male albino mice with the mean body mass of 25 g (aged 5–6 weeks) were used 
in the experiments. Animals were maintained under a 12/12 h light/dark cycle, fed ad libi-
tum a stock laboratory diet (%, m/m: 49.8 carbohydrates, 23.5 protein, 3.7 fats, minerals and 
added vitamins and amino acids) and had free access to drinking water.
Brain GABA-T activity determination
Tissue processing. – After appropriate treatment, animals were sacrificed and whole 
wet brains were removed. Homogenates were prepared in 5 % Triton X-100 solution (25 %, 
m/V) in a tissue homogenizer (Glas-Col, USA). After centrifugation at 12,500 rpm for 45 
min, GABA-T activity was determined in the supernatants.
Enzymatic activity evaluation. – GABA-T activity quantification was performed accord-
ing to the method of Jung et al. (22) using 6 µmol L–1 GABA plus 5 µmol L–1 2-oxoglutarate 
as substrate. Enzymatic activity was proportional to the formation of NADH from NAD, 
which was recorded as the increase in absorbance at 340 nm. Specific GABA-T activity was 
calculated by subtracting the blank values (measured in the absence of substrate) from the 
total activity. The anticonvulsant AAOA was employed as a control in all cases.
In vitro effect of NO on brain GABA-T activity
To the supernatants obtained from mouse brain homogenates, different concentra-
tions of l-Arg (10–5–10–3 mol L–1), L-NAME (10–4–10–3 mol L–1), 7-NI (10–5–10–3 mol L–1) or 
AAOA (10–3 mol L–1) were added. Several minutes afterwards (10, 15, 20 or 30 min), GABA-
T activity was determined. Enzymatic activity was compared to that of homogenates from 
animals that did not receive any treatment.
Ex vivo effect of NO on GABA-T activity
Groups of 5 animals each received different doses of l-Arg (30–250 mg kg–1), L-NAME 
(10–200 mg kg–1), 7-NI (10–50 mg kg–1) or AAOA (20–50 mg kg–1) via i.p. Animals were sac-
rificed one hour after administration, brains were quickly removed and GABA-T activity 
was determined.
In a different set of experiments, l-Arg (50 mg kg–1), L-NAME (50 and 100 mg kg–1), 
7-NI (10 mg kg–1) or AAOA (40 mg kg–1) were i.p. administrated to groups of 5 animals each. 
After 1 hour of exposure to the respective agent, animals received PTZ (95 mg kg–1). Twenty 
minutes later, animals were sacrificed and GABA-T activity was determined. Similar ex-
periments were performed at the same time under the same conditions, but without PTZ 
administration.
In all cases, enzymatic activity was compared to that of animals that received only 
saline solution.
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Determination of brain GABA concentration 
Tissue processing. – Animals were sacrificed and whole brains were removed. Homog-
enates in 80 % ethanol were obtained with a Glas-Col tissue homogenizer. Homogenates 
were centrifuged (3,500 rpm/5 min), pellets were washed in 75 % ethanol and centrifuged 
at 5000 rpm for 5 min. Supernatants were brought together and chloroform was added. 
After vigorous shaking and centrifugation at 3,000 rpm for 20 min, the aqueous phase was 
extracted and concentrated. Aliquots of this sample were used for GABA quantification. 
Enzymatic quantification of GABA. – GABA quantification was performed with GABase 
according to the manufacturer’s instructions (Sigma Chemical Co). Briefly, in this method 
GABA-T converts GABA to succinate semialdehyde (SSA). SSA is then converted to succi-
nate in a reaction catalyzed by SSDH, using NAD(P)+ as a cofactor. Stoichiometric reduc-
tion of the cofactor, resulting in the increment of the absorbance at 340 nm, reflects the 
levels of GABA in the reaction mixture. Reaction medium was composed of pyrophos-
phate buffer pH = 8.6, NADP 0.004 mol L–1, pH = 7, GABA solution and alpha ketoglutaric 
acid 0.02 mol L–1, pH = 7.9. AAOA was used as a control in all experiments.
Ex vivo effect of NO on GABA brain levels
Different doses of l-Arg (30–250 mg kg–1), L-NAME (10–200 mg kg–1), 7-NI (10–50 mg 
kg–1) or AAOA (20–50 mg kg–1) were i.p. administrated to groups of 5 animals each. Ani-
mals were sacrificed after 1 hour, the brains were quickly removed and GABA levels were 
quantified.
In all cases, GABA concentration was compared with the GABA concentration in 
animals of the control group, which received only saline solution.
Statistical analysis
All results were normalized against the control and expressed as the mean ± SEM 
(standard error of the mean) of at least five determinations (n > 5). GABA-T activity was 
compared between groups using the one-way analysis of variance (ANOVA). F-value was 
Fig. 1. In vitro influence of some nitric oxide synthase (NOS) effectors on mouse brain gamma amino 
butyric acid transaminase (GABA-T) activity. a) l-arginine (l-Arg), b) Nω-nitro-l-arginine methyl 
ester (L-NAME), c) 7-nitroindazole (7-NI) and amino-oxyacetic acid (AAOA). Results are mean ± SEM 
(n > 4). *Significantly different compared to the control: p < 0.05.
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calculated and, if and where indicated, followed by Tukey’s multiple comparison test. 
Graph Pad Prism version 5.0 software (GraphPad Software, Inc, La Jolla, CA, USA) was 
used, and p < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
The aim of this work was to investigate the effect of NO on GABA-T activity and brain 
GABA levels in order to find out why moderate and high increases in NO levels had op-
posite effects on GABA-T activity, as reported by Paul et al. (18). NO levels were modified 
by influencing the NOS activity with its natural substrate (l-Arg) and with unspecific 
 (L-NAME) and neuronal NOS specific (7-NI) inhibitors of its activity, and the resulting 
changes in GABA-T activity and GABA levels were analyzed in vitro as well as ex vivo. 
AAOA, a traditional GABA-T inhibitor, was used as a positive control.
Fig. 2. Ex vivo influence of some nitric oxide synthase (NOS) effectors on mouse brain gamma amino 
butyric acid transaminase (GABA-T) activity and brain GABA levels. a) l-arginine (l-Arg, 30–250 
mg kg–1), b) Nω-nitro-l-arginine methyl ester (L-NAME, 10–200 mg kg–1), c) 7-nitroindazole (7-NI, 
10–50 mg kg–1) or d) amino-oxyacetic acid (AAOA, 20–50 mg kg–1). Results are mean ± SEM (n > 4). 
*Significantly different compared to the control: p < 0.05. 
a)                                                                                b)
c)                                                                                d)
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l-Arg, 10–3 mol L–1, significantly decreased GABA-T activity in a dose dependent man-
ner in vitro, reaching an activity of only 10 % compared to the control (Fig. 1a). L-NAME 
increased GABA-T activity in a dose response manner up to 700 % compared to the control 
(Fig. 1b). The described in vitro variations of GABA-T activity induced by changes in NO 
levels indicate a clear correlation between these parameters, and are in accord with the 
reports of Jayakumar et al. (17) and Paul et al. (18, 23).
Considering only the results for L-NAME, it could be presumed that an in vitro in-
duced decrease in NO levels caused an increase in GABA-T activity. However, since L-
NAME is a non-specific NOS inhibitor with an affinity for eNOS of 63–75 % and only of 7 
% for nNOS, its high concentration would be necessary to inhibit the latter NOS isoform. 
In other words, the role of nNOS is difficult to determine using L-NAME. Thus, a more 
selective inhibitor of this NO isoform, 7-NI, was used.
Similarly as L-NAME, 7-NI enhanced GABA-T activity but by a much bigger amount, 
reaching 1.500 % of activity at 10–4 mol L–1 compared to the control group (Fig. 1c). An about 
15-fold rise of enzymatic activity compared to the control suggests the important role of 
nNOS in the modulation of GABA-T activity. Considering that high concentrations of L-
NAME had effects similar to low 7-NI concentrations, the effects of high concentrations of 
L-NAME on GABA-T activity could be attributed to the inhibition of nNOS. 
Fig. 2 represents ex vivo effects of the different NOS effectors. It could be presumed 
that l-Arg decreased GABA-T activity at two different stages, represented by two different 
picks. First, NO levels decreased by 40–50 % at a dose of 60 mg kg–1, returning slowly to 
the control levels at a dose of 190 mg kg–1. In a second peak or stage, GABA-T activity 
dropped once again by 40–50 % at a dose of 250 mg kg–1 (Fig. 2a). Therefore, it could be 
taken that the diminished GABA-T activity generated by NO is observed not only in vitro 
but also ex vivo, but showing two stages, which will be called biphasic. This biphasic shape 
may represent the effect of NO generated by different NOS isoforms, implying different 
effects of NO on GABA-T activity, which could depend on whether it is generated by eNOS 
or nNOS (location dependent).
The former hypothesis seems to be enforced by the effects of different doses of L-
NAME (Fig. 2b), which also shows two peaks, reaching an increase of 225 % compared to 
the control (40 mg kg–1), whereas higher doses decreased the activity, reaching a 50 % activ-
ity compared to the control.
As regards the effects of 7-NI ex vivo, it decreased GABA-T in a dose dependent man-
ner, reaching about 40 % of enzymatic activity compared to the control  and showing only 
one peak (Fig. 2c). Considering the specific inhibition of 7-NI on nNOS and that its inhibi-
tion on GABA-T activity did not show a biphasic effect, along with the fact that 7-NI de-
creased enzymatic activity by a similar magnitude to that observed at the higher tested 
dose of L-NAME, it is proposed that the increase of GABA-T activity may be attributed to 
the inhibition of eNOS, whereas the diminution of the enzymatic activity could be consid-
ered as a result of nNOS inhibition.
Overall, ex vivo results suggest that endothelial and neuronal NO have opposite effects 
on GABA-T activity and their effect as an activator or inhibitor of the enzyme may be re-
lated to their anticonvulsant or proconvulsant properties. Therefore, NO brain levels may 
constitute a new mechanism for GABA-T activity regulation, modulating different path-
ways and suggesting a possible dependence on location (in the glia or in neurons). This 
hypothesis, however, needs further investigation.
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In vitro results for 7-NI are opposite to those observed in vivo, since it caused an in-
crease but also a decrease of GABA-T activity, resp. In vitro experiments were designed to 
study the direct effect of drugs on GABA-T activity without the influence of any other 
factor, whereas in vivo studies showed the effect on enzymatic activity as a result of inte-
gral effects of drugs on the different body systems. Thus, the contrast between in vitro and 
in vivo effects of 7-NI is considered to be the result of its effect not only on the enzyme but 
also on other systems that may influence GABA-T activity. Since brain GABA-T is the sub-
ject of this study, the effects of NO on the nervous system, which may have repercussions 
on GABA-T activity, are of particular interest. For example, it has been reported that NO 
evokes the release of several neurotransmitters, including GABA (7, 24).
Considering the forgoing and the role of GABA-T on the regulation of GABA brain 
levels, l-Arg, L-NAME and 7-NI effects on brain GABA levels were also investigated. l-Arg 
increased brain GABA levels, showing also two different peaks (Fig. 2a). This means that 
an increase in NO levels induced by l-Arg induced, in turn, an increase of brain GABA 
levels, in a biphasic process corresponding to the two stages of the effect of NO on GABA-
T activity. This is in accord with the findings of several authors (7, 15, 16). The fact that 
sodium nitroprusside, another NO donor, also increased brain GABA levels (18) supports 
the idea that NO could modulate the GABA-ergic system.
The effect of L-NAME on brain GABA levels show also two peaks, diminishes with 
the dose up to 75 mg kg–1 but rises with 100 mg kg–1 or higher (Fig. 2b). This is in agreement 
with the biphasic effect of L-NAME on GABA-T activity  and with the biphasic modulation 
of GABA release by NO from rat hippocampus reported by Getting et al. (25).
7-NI increased brain GABA levels in a dose dependent manner (Fig. 2c) to a value 
similar to the highest dose of L-NAME (Fig. 2c), but showed only one peak. The described 
increase in GABA levels may explain the enhanced anticonvulsant effects of conventional 
antiepileptic drugs such as carbamazepine, phenobarbital, phenytoin and valproate in-
duced by 7-NI, obtained in maximal electroshock-induced seizures in a mouse model (26).
Altogether, the described effects on brain GABA levels confirm that NO promotes the 
release of GABA and suggest that this happens through the changes in GABA-T activity. 
Besides, considering the results for L-NAME and 7-NI and their affinity for eNOS and 
nNOS, resp., it could be said that neuronal and endothelial NO have opposite effects not 
only on GABA-T activity but also on brain GABA levels.
Opposite effects of NO, depending on whether eNOS or nNOS is involved, may ex-
plain its anticonvulsant but also proconvulsant properties, as reported in different studies 
(4). Considering that NO as well as GABA-T activity are related to seizures, the possible 
repercussions of the changes of NO levels on GABA-T activity during convulsions were 
also studied, investigating the effect of l-Arg, L-NAME and 7-NI on GABA-T activity dur-
ing seizures induced by PTZ.
PTZ did not modify GABA-T activity by itself but the decrease of GABA-T activity 
caused by 50 mg kg–1 of l-Arg as well as the increase produced by 50 mg kg–1 of L-NAME 
were partially counteracted during the seizures induced by PTZ. L-NAME 150 mg kg–1 and 
7-NI 10 mg kg–1 decreased enzymatic activity by a similar value (about 60 %), the effect that 
was not modified by PTZ (Fig. 3). The increase in enzymatic activity induced by a low dose 
of L-NAME and the decrease caused by a high dose of the same drug indicate that also 
during seizures induced by PTZ, L-NAME had different effects on GABA-T activity and, 
in turn, on brain GABA levels, which seems to be related to the NOS isoform involved.
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The primary target of PTZ is to weaken  the inhibitory action of GABA, acting as a 
GABAA receptor antagonist. However, seizures induced by this chemoconvulsant are also 
a result of the activation of glutamatergic synaptic transmission, and NMDA receptors are 
mainly involved in the genesis of clonic seizures (27). The results reported herein suggest 
that NO generated by nNOS may be the activator of NMDA receptors that participate in 
this process, since during seizures induced by PTZ inhibition of nNOS, caused by high 
doses of L-NAME as well as 7-NI, it decreased GABA-T activity leading to an increase of 
brain GABA levels. This conclusion is not surprising considering that it has been reported 
Fig. 3. Ex vivo influence of some nitric oxide synthase (NOS) effectors on mouse brain gamma amino 
butyric acid transaminase (GABA-T) activity during seizures induced by pentylenetetrazole (PTZ). 
Animals received l-arginine (l-Arg, 50 mg kg–1), Nω-nitro-l-arginine methyl ester (L-NAME, 50 and 
150 mg kg–1), 7-nitroindazole (7-NI, 10 mg kg–1) or amino-oxyacetic acid (AAOA, 40 mg kg–1). Seizures 
were induced by PTZ (95 mg kg–1). Results are mean ± SEM (n > 4). *Significantly different from the 
group that did not receive PTZ: p < 0.05.
Fig. 4. Correlation between brain gamma amino butyric acid transaminase (GABA-T) activity and brain 
GABA levels under the influence of l-arginine (l-Arg), Nω-nitro-l-arginine methyl ester (L-NAME) 
and 7-nitroindazole (7-NI).
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that NMDA receptors/NO pathway contribute to the anticonvulsant effect of different 
drugs such as D-penicillamine (11), dextrometrophan (28) and lithium (29).
Once established that NO influences the GABA-T activity modulating brain GABA 
levels, the correlations between GABA-T activity and GABA levels in the presence of L-
Arg, L-NAME and 7-NI were explored. Fig. 4 shows, as expected, that GABA-T activity and 
brain GABA levels are inversely related, but only in the case of 7-NI (Fig. 4c) the correlation 
is linear with R2 = 0.986. These results suggest that NO generated by nNOS had a direct 
influence on GABA-T activity and thereby on brain GABA levels.
CONCLUSIONS
Contradictory reports on the role of NO on the seizure mechanism may be explained 
by the NOS isoform involved. The results confer anticonvulsant properties on endothelial 
NO but proconvulsant on neuronal NOS. This attribution of convulsant properties to neu-
ronal NO is in agreement with the finding that the anticonvulsant effect of dextrometro-
phan is mediated by a decline in nNOS activity (28). Proconvulsant or anticonvulsant 
properties of NO may be explained by the opposite effects of endothelial and neuronal NO 
on GABA-T activity, and hence on GABA levels.
More work is necessary to assess exactly the role of neuronal NO and its particular 
action site, since it has different effects on the brain. For example, it has been reported that 
nNOS- derived excess NO in the glutamatergic pathway plays a key role in the failure of 
the blood-brain-barrier during seizures induced by PTZ (30).
Understanding how to modulate brain GABA-T activity through NO brain levels rep-
resents a novel strategy for controlling seizures, and hence for the development of new 
antiepileptic drugs (AEDS), which is especially important in the cases refractory to the 
treatment with traditional AEDS, either administered alone or in combination.
Acknowledgements. – This work was supported by the Section of Postgraduate Studies and Re-
search, Academic Secretary of National Polytechnic Institute, México.
Acronyms, abbreviations, symbols. – AAOA – amino oxyacetic acid, AEDS – antiepileptic drugs, 
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– N-methyl-d-aspartate (NMDA), NO – nitric oxide, NOS – NO synthase (eNOS – endothelial NOS, 
iNOS – inducible NOS, nNOS – neuronal NOS), PTZ – pentylenetetrazole, SSA – succinate semialde-
hyde, SSDH – succinic semialdehyde dehydrogenase.
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